Pankit Vachhani, MD, University of Alabama at Birmingham Hospital

Articles

Unmet Needs in Management of Myeloproliferative Neoplasms

August 18th 2021

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Selecting Therapy to Treat Myelofibrosis

August 18th 2021

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.

Ruxolitinib for Myelofibrosis: Treatment Considerations

August 18th 2021

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.

Myelofibrosis: Treatment Planning and Management

August 11th 2021

Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.

Treatment Approaches for Myelofibrosis

August 11th 2021

Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.

Risk Stratification: Primary Myelofibrosis

August 11th 2021

An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.

Bone Marrow Transplant for Patients With MF

July 20th 2021

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Fedratinib for Patients With Primary Myelofibrosis

July 13th 2021

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

Ruxolitinib for Patients With Primary Myelofibrosis

July 13th 2021

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

Monitoring Disease Response or Progression in MF

July 6th 2021

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Recent Updates to NCCN Guidelines on MF Treatment

July 6th 2021

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Therapeutic Decision-Making for Primary Myelofibrosis

June 29th 2021

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

Diagnosis and Prognosis of Primary Myelofibrosis

June 29th 2021

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.